AIM To explore the anti-diabetic effects of berberine and its influence on insulin secretion. METHODS Impaired glucose tolerance rats induced by iv injection of streptozotocin 30 mg/kg were treated with berberine 187.5 and 562.5 mg/kg while fed with high fat laboratory chow. After rats were treated for 4 weeks, oral glucose tolerance was determined, and for 8 weeks, the fasting blood glucose, insulin, lipid series were determined. In insulin secretion experiments, berberine 93.75, 187.5, and 562.5 mg/kg was administered orally to BALB/c mice at a bolus. The murine serum was collected 2 h after the berberine administration for insulin determination. Insulin released from HIT-T15 cells and pancreatic islets incubated with berberine 1-100 micromol/L for 12 h was determined. RESULTS The levels of fasting blood glucose (7.4+/-1.5 or 7.3+/-1.3 vs 9.3+/-1.3 mmol/L), triglycerides (0.61+/-0.22 or 0.63+/-0.17 vs 1.8+/-0.7 mmol/L), total cholesterol (1.8+/-0.3 or 1.9+/-0.3 vs 2.2+/-0.2 mmol/L), free fatty acid (456+/-93 or 460+/-72 vs 550+/-113 micromol/L) and apolipoprotein B (0.37+/-0.02 or 0.42+/-0.05 vs 0.46+/-0.04 g/L) were reduced greatly in berberine-treated groups at doses of 187.5 and 562.5 mg/g/d, respectively as compared with those in control group (P<0.05 or P<0.01), whereas high density lipoprotein-cholesterol (1.5+/-0.3 or 1.4+/-0.3 vs 1.1+/-0.1 g/L), apolipoprotein AI (0.80+/-0.08 or 0.87+/-0.08 vs 0.71+/-0.06 g/L) were significantly increased (P<0.05 or P<0.01), and oral glucose tolerance was improved. In vitro experiment showed that berberine 1-10 micromol/L facilitated insulin secretion of HIT-T15 cells and murine pancreatic islets in a dose-dependent manner. Meanwhile murine serum insulin level (27.5+/-2.7 or 29+/-4 or 29+/-4 vs 24.3+/-2.8 pIU/L) was undoubtedly promoted and blood glucose (4.52+/-0.31 or 4.45+/-0.29 or 4.30+/-0.19 vs 4.87+/-0.21 mmol/L) was reduced after berberine administration at doses of 93.75, 187.5, and 562.5 mg/kg, respectively in the BALB/c mice. CONCLUSION Berberine possesses anti-diabetic effects, which is related to the property of stimulating insulin secretion and modulating lipids.

中文翻译：

---

小ber碱对糖耐量减低大鼠的治疗作用及其对胰岛素分泌的影响。

目的探讨小ber碱的抗糖尿病作用及其对胰岛素分泌的影响。方法静脉注射30 mg / kg链脲佐菌素诱导的葡萄糖耐量减低的大鼠在饲喂高脂实验室食物的同时给予小7.5碱187.5和562.5 mg / kg。处理大鼠4周后，确定口服葡萄糖耐量，并在8周内确定空腹血糖，胰岛素，脂质系列。在胰岛素分泌实验中，以大剂量口服将小ber碱93.75、187.5和562.5 mg / kg口服给予BALB / c小鼠。小the碱给药2小时后收集鼠血清用于胰岛素测定。测定从HIT-T15细胞和胰岛中与小ber碱1-100 micromol / L孵育12小时后释放的胰岛素。结果空腹血糖水平（7.4 +/- 1.5或7.3 +/- 1.3与9。3 +/- 1.3 mmol / L），甘油三酸酯（0.61 +/- 0.22或0.63 +/- 0.17对1.8 +/- 0.7 mmol / L），总胆固醇（1.8 +/- 0.3或1.9 +/- 0.3对2.2 +/- 0.2 mmol / L），游离脂肪酸（456 +/- 93或460 +/- 72 vs 550 +/- 113 micromol / L）和载脂蛋白B（0.37 +/- 0.02或0.42 +/- 0.05 vs小control碱治疗组分别以187.5和562.5 mg / g / d的剂量分别较对照组降低了0.46 +/- 0.04 g / L）（P <0.05或P <0.01），而高密度脂蛋白胆固醇（1.5 +/- 0.3或1.4 +/- 0.3 vs 1.1 +/- 0.1 g / L），载脂蛋白AI（0.80 +/- 0.08或0.87 +/- 0.08 vs 0.71 +/- 0.06 g / L）显着增加（P <0.05或P <0.01），并且口服葡萄糖耐量得到改善。体外实验表明，小ber碱1-10 micromol / L以剂量依赖的方式促进HIT-T15细胞和鼠胰岛的胰岛素分泌。同时，无疑地提高了鼠血清胰岛素水平（27.5 +/- 2.7或29 +/- 4或29 +/- 4与24.3 +/- 2.8 pIU / L），血糖水平升高（4.52 +/- 0.31或4.45 +/-）。在BALB / c小鼠中，分别以93.75、187.5和562.5 mg / kg的剂量施用小ber碱后，血脂降低了0.29或4.30 +/- 0.19 vs. 4.87 +/- 0.21 mmol / L）。结论小Ber碱具有抗糖尿病作用，其与刺激胰岛素分泌和调节脂质的性质有关。